Clinical trial • Phase III • Neurology

NTRX-07 for Neuroinflammation-related diseases | Alzheimer's disease

Phase III trial of NTRX-07 for Neuroinflammation-related diseases | Alzheimer's disease. 24 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Neuroinflammation-related diseases | Alzheimer's disease
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
26-09-2025
First CTIS Authorization Date
19-11-2025

Trial design

Phase III trial across 1 site in Hungary.

Target Sample Size
24
Trial Duration For Participant
74

Eligibility

Recruits 24 isVulnerablePopulationSelected: true; no details on consent or assent handling available in the record.

Vulnerable Population
isVulnerablePopulationSelected: true; no details on consent or assent handling available in the record

Recruitment

Planned Sample Size
24
Recruitment Window Months
2

Geography

Total Number Of Sites
1
Total Number Of Participants
24

Hungary

Earliest CTIS Part Ii Submission Date
03-11-2025
Latest Decision Or Authorization Date
19-11-2025
Processing Time Days
16
Number Of Sites
1
Number Of Participants
24

Sites

Site Name
CRU Hungary Kft.
Department Name
Early Phase Unit
Contact Person Name
Géza Lakner
Contact Person Email
info@cruint.com
Number Of Participants
24

Sponsor

Primary sponsor

Full Name
Neurotherapia Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
NTRX-07

Related trials

Other published trials that may interest you.